Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Early Breast Cancer
Interventions: Ribociclib, Endocrine Therapy (ET); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 73
States / cities: Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: SMS995, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Cystic Fibrosis
Interventions: Pancrelipase Delayed Release, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Sunscreen
Interventions: Sunscreen A, Sunscreen B, Sunscreen C; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: ADHD
Interventions: methylphenidate transdermal system, Placebo; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more

Conditions: Parkinson's Disease
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: Tel-Aviv Sourasky Medical Center; Government
Eligibility: 25 Years to 90 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Onychomycosis of Toenails
Interventions: AN2690 Topical Solution, 5%, Solution Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 27
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more

Conditions: Coronary Occlusion
Interventions: NovaCross; Device
Lead sponsor: Nitiloop Ltd.; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Little Rock, Arkansas • New York, New York • York, Pennsylvania

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more

Conditions: Cystic Fibrosis
Interventions: Aeroquin, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 95
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more

Conditions: Bacterial Infection
Interventions: Meropenem, Standard antibiotic therapy; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Birmingham, Alabama • Newark, Delaware • Miami, Florida + 7 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: G17DT Immunogen, cisplatin, fluorouracil; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more

Conditions: Dystonia, Focal, Task-specific
Interventions: rTMS, Sham rTMS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Endometrial Cancer
Interventions: Sapanisertib, Serabelisib, Paclitaxel; Drug
Lead sponsor: Faeth Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more

Conditions: Tuberous Sclerosis
Interventions: JASPER; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months to 40 Months
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Influenza
Interventions: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 10
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Mild Hepatic Encephalopathy
Interventions: AST-120; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more

Conditions: Acromegaly
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Torrance, California + 21 more

Conditions: Healthy
Interventions: HEPLISAV and/or Placebo, Engerix-B; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 2,452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 29
States / cities: Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more

Search by objective public record fields.

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease

Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Cohort B of the Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

JASPER Early Intervention for Tuberous Sclerosis

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

AST-120 Used to Treat Mild Hepatic Encephalopathy

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine